Vaishali. R. Undale, Sujata S. Kurkute, Srutuja S. Jadhav
email@example.com , firstname.lastname@example.org , email@example.com
Dr. Vaishali. R. Undale1, Sujata S. Kurkute2, Srutuja S. Jadhav2
1HOD, Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune-411018.
2Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune-411018.
Volume - 13,
Issue - 6,
Year - 2020
Type 2 diabetes mellitus is a metabolic disease characterized by persistent hyperglycemia. High blood sugar can produce long-term complications such as cardiovascular and renal disorders, retinopathy, and poor blood flow. The pharmacotherapy of diabetes includes use of oral hypoglycaemic agents like insulin and oral hypoglycaemic agents such as biguanides, sulphonylureas, insulin analogues, alpha glucosidase and amylse inhibitors, gliptins etc. Though these agents are therapeutically beneficial, they are associated with adverse effects such as hypoglycaemia, vitamin B12 deficiency, weight gain, etc. The alternatives as herbs and/or phytoconstituents, exercise, yoga, etc have been explored widely for treatment and management of diabetes mellitus. Number of plants and their isolated phytoconstituents are proven for antidiabetic activity in preclinical and clinical studies and one of widely explored of them is Curcumin. The Curcumin in its nanoparicles form had been already proven for potential antidiabetic activity. Though the phytoconstituents are said to be safe their interactions with modern medicines might be either beneficial or harmful and should be considered while co-administration of them. This research work focuses on evaluation of drug interaction between CuNPs and Metformin in STZ-Nicotinamide induced hyperglycemia in Wistar rats. The physical incompatibility between curcumin and metformin was not observed in the study. The coadministration of both produced significant reduction in glycemic and oxidative parameters than only metformin treated animals. The study suggest coadministration of curcumin and metformin can be used for better and safe management and treatment of diabetes mellitus.
Cite this article:
Vaishali. R. Undale, Sujata S. Kurkute, Srutuja S. Jadhav. Curcumin Potentiates Therapeutic Efficacy of Metformin: A Preclinical Study in STZ-NA Induced Hyperglycemia in Wistar Rats. Research J. Pharm. and Tech 2020; 13(6):2591-2596. doi: 10.5958/0974-360X.2020.00461.8
1. Chaudhury A, Duvoor C, Dendi R, Sena V, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat NS, Montales MT, Kuriakose K. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Frontiers in Endocrinology. 2017 Jan 24; 8:6.
2. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes care. 2004 Jan 1;27(1):256-63.
3. Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress—a concise review. Saudi Pharmaceutical Journal. 2016 Sep 1;24(5):547-53.
4. Abdel-Mageid AD, Abou-Salem ME, Salaam NM, El-Garhy HA. The potential effect of garlic extract and curcumin nanoparticles against complication accompanied with experimentally induced diabetes in rats. Phytomedicine. 2018 Apr 1; 43:126-34.
5. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018 Feb;14(2):88.
6. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Medical Journal. 2012 Jul;27(4):269.
7. Ghorbani A, Jalali SA, Varedi M. Isolation of adipose tissue mesenchymal stem cells without tissue destruction: a non-enzymatic method. Tissue and Cell. 2014 Feb 1;46(1):54-8.
8. Ghasemi A, Khalifi S, Jedi S. Streptozotocin-nicotinamide-induced rat model of type 2 diabetes. Acta Physiologica Hungarica. 2014 Dec 1;101(4):408-20.
9. Bailey CJ, Turner RC. Metformin. New England Journal of Medicine. 1996 Feb 29;334(9):574-9.
10. Umpierrez G, Povedano ST, Manghi FP, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes care. 2014 Aug 1;37(8):2168-76.
11. Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Critical reviews in food science and nutrition. 2017 Sep 2;57(13):2889-95.
12. Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. Evidence-Based Complementary and Alternative Medicine. 2013;2013.
13. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB. Retracted: Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo.
14. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. European Journal of Pharmaceutical Sciences. 2009 Jun 28;37(3-4):223-30.
15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet. 2002 Jun 15;359(9323):2072-7.